Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1 Study Of ALN-BCAT As Monotherapy And In Combination With Pembrolizumab In Patients With Advanced Or Metastatic Hepatocellular Carcinoma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
-
Phase III, Randomized, Open-label, Global, Multicenter Study Of Rilvegostomig Or Durvalumab In Combination With Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
Contact Us for the Latest Status
.